Drug Trial Radar · NCT05374525
A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States
Last checked: Nov 20, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
287
Actual
Start
May 18, 2022
Primary completion
Aug 8, 2024
Study completion Aug 8, 2024
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- First posted
- May 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a two-arm study evaluating the impact of two implementation strategy conditions, dynamic implementation and routine implementation on the feasibility of delivering of Cabotegravir PrEP in low and high-volume PrEP sites in the United States for men who have sex with men (MSM) and Transgender men ≥ 18 years of age. There are two types of participants in the study. Patient Study Participants (PSPs) will refer to individuals who are enrolled in the study and who will receive commercially available Cabotegravir PrEP via prescription from the PrEP provider at the corresponding site. Staff Study Participants (SSPs) will refer to site staff who are involved in administrative and clinical aspects of offering and administering PrEP to PSPs and will participate in the staff study assessments. PSPs who choose to opt for 1-month oral lead-in (OLI) will receive cabotegravir tablets for PrEP at Month 1 followed by APPRETUDE intramuscular (IM) injections on Month 2, 3 and every two months thereafter up to Month 13. PSPs who opt for Direct to injections (DTI) will receive APPRETUDE IM injections on Month 1, 2 and every two months thereafter up to Month 12. Month 6/7 refers to Month 6 (DTI)/ Month 7 (OLI). Month 12/13 refers to Month 12 (DTI)/ Month 13 (OLI).
Conditions
- HIV Infections
Interventions
APRETUDEDrug
Available as intramuscular injection.
Cabotegravir OLIDrug
Available as marketed orally administered tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Feasibility of Intervention Measure (FIM) Score Assessed for SSPsTime frame: At Month 12
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
San Francisco, California
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Pensacola, Florida
GSK Investigational Site
Sarasota, Florida
GSK Investigational Site
Bridgeport, Kansas
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Columbia, Missouri
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Rochester, New York
GSK Investigational Site
The Bronx, New York
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Charleston, South Carolina
GSK Investigational Site
Harlingen, Texas
GSK Investigational Site
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.